Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improved motor function in Parkinson's disease models, and is a potential candidate compound for treatment of Parkinson's disease.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 80,500 |
5 mg | 在庫あり | ¥ 190,000 |
10 mg | 在庫あり | ¥ 259,500 |
25 mg | 在庫あり | ¥ 365,000 |
50 mg | 在庫あり | ¥ 454,500 |
100 mg | 在庫あり | ¥ 574,000 |
500 mg | 在庫あり | ¥ 1,124,500 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 164,500 |
説明 | UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improved motor function in Parkinson's disease models, and is a potential candidate compound for treatment of Parkinson's disease. |
In vivo | After i.v. administration of UK-240455 to male rats, UK-240455 exhibits a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 shows a decrease with an apparent half-life of 0.4 h. The analysis of urine (0 to 24 h) reveals that 57% of the administered dose is excreted unchanged. Thus, the urine clearance rate of UK-240455 in rats amounts to 7 mL/min/kg. Upon oral administration to male rats, the apparent elimination half-life of UK-240455 from plasma was observed to be 1.6 hours.[1] |
分子量 | 368.19 |
分子式 | C11H11Cl2N3O5S |
CAS No. | 178908-09-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12 mg/mL (32.59 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UK-240455 178908-09-3 Membrane transporter/Ion channel Neuroscience NMDAR iGluR UK240455 UK 240455 Inhibitor inhibitor inhibit